论文信息 - Fernmetastasiertes Melanom: neue Therapiestudien - 字舞流文

Fernmetastasiertes Melanom: neue Therapiestudien

[1] R. Fisher,et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma , 2019, Nature Medicine.

[2] R. Sullivan,et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients , 2019, Nature Medicine.

[3] P. Ascierto,et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma , 2019, Nature Medicine.

[4] D. Schadendorf,et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. , 2019, Journal of Clinical Oncology.

[5] M. Hurwitz,et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. , 2019, Journal of Clinical Oncology.

[6] James R. Anderson,et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. , 2018 .